Amisulpride D2/5HT2 Antagonism for PONV Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Postoperative nausea and vomiting (PONV) remains a significant issue in surgical patients, affecting approximately 30% of all surgical patients and 70% of high-risk patients, despite routine use of prophylactic anti-emetics, with existing agents showing limited efficacy and potential for adverse effects, particularly in high-risk groups.
Innovation Solution
Amisulpride, a dopamine D2/serotonin 5HT2 antagonist, is administered as a single chiral enantiomer or racemate, particularly effective in high-risk patients with multiple risk factors for PONV, such as history of nausea, non-smoking status, and female gender, offering a higher relative risk reduction in postoperative emesis incidence when used in combination with other anti-emetic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If routine prophylactic anti-emetics are used in moderate and high-risk patients, then PONV prevention is provided, but PONV still occurs in about 30% of cases
Solution Approach 1:
The patent introduces amisulpride, a dopamine D2/serotonin 5HT2 antagonist with a different mechanism of action compared to existing 5HT3 antagonists and NK1 antagonists. This represents a parameter change in the pharmacological approach by targeting different receptor systems (dopaminergic and serotoninergic pathways) to achieve enhanced anti-emetic efficacy where conventional agents have failed
Solution Approach 2:
The patent promotes combination therapy using amisulpride together with other anti-emetic agents from different classes (5HT3 antagonists like ondansetron, granisetron, palonosetron; NK1 antagonists like aprepitant, netupitant, rolapitant; or dexamethasone). This composite approach combines multiple mechanisms of action to provide synergistic protection against PONV, reducing the 30% residual incidence through multi-target coverage
2Adaptability or versatility
If existing anti-emetic agents are used, then some PONV protection is achieved, but there remains a significant need for additional agents with different mechanisms of action
Solution Approach 1:
Amisulpride exhibits multi-functionality by acting on both dopamine D2 and serotonin 5HT2 receptors simultaneously. This dual mechanism provides versatile anti-emetic coverage that complements existing single-mechanism agents, filling the gap for medications with different modes of action while maintaining broad spectrum effectiveness across diverse patient populations and surgical types
3Reliability
If combination therapy with amisulpride and other anti-emetic agents is used, then relative risk reduction of 31% in emesis occurrence is achieved, but drug interaction complexity increases
Solution Approach 1:
Amisulpride serves as an intermediary agent that bridges different anti-emetic mechanisms by combining dopaminergic and serotoninergic blockade. When used in combination with 5HT3 antagonists, NK1 antagonists, or dexamethasone, it acts as a complementary mediator that enhances overall efficacy through synergistic interactions, achieving 31% relative risk reduction while the dosing guidelines simplify the management of this multi-component therapy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Amisulpride significantly reduces the incidence of postoperative emesis, achieving a relative risk reduction of 31% in the occurrence of vomiting and/or retching, with a complete response rate improvement of 20.8% compared to placebo, demonstrating its efficacy in preventing PONV in high-risk surgical patients.
Implementation Method 1
Amisulpride, a dopamine D2/serotonin 5HT2 antagonist
Implementation Method 2
Amisulpride, a dopamine D2/serotonin 5HT2 antagonist
Data Source
AI summary
Amisulpride is useful in the therapy (particularly the prevention) of postoperative emesis in a patient, particularly wherein the patient is undergoing a surgical procedure where postoperative emesis would be potentially dangerous to the patient.